On Monday, Oppenheimer maintained its Outperform rating and $15.00 price target on Savara (NASDAQ:), a pharmaceutical company focused on rare respiratory diseases. The firm’s confidence in the stock is bolstered by the commercial potential of Savara’s Molbreevi for the treatment of autoimmune Pulmonary Alveolar Proteinosis (aPAP), a rare lung condition currently without any approved pharmacological treatments.
Molbreevi’s Phase 3 IMPALA-2 trial results have strengthened the optimism surrounding its prospects. The trial demonstrated a statistically significant improvement in lung function, specifically a 6% increase in Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO) at Week 24 and a sustained 6.9% improvement at Week 48. These outcomes have exceeded initial expectations and suggest that Molbreevi could become a successful treatment option for aPAP patients.
Market research supports the potential for Molbreevi’s adoption and coverage. According to management, approximately 85% of the 3,600 confirmed aPAP patients in the United States could be eligible for treatment upon launch. This aligns with surveys indicating that a majority of pulmonologists would likely prescribe the treatment, most payers intend to provide coverage, and patients have expressed a strong willingness to use the drug.
With the anticipated Biologics License Application (BLA) submission expected in the first half of 2025, Oppenheimer’s reiteration of the Outperform rating and price target reflects a positive outlook for Savara’s future commercial activities. The firm’s analysis suggests that Molbreevi’s market entry could significantly impact Savara’s valuation, given the unmet medical need in aPAP treatment.
In other recent news, Savara Inc. reported earnings per share at ($0.12), slightly below the ($0.10) forecasted by Oppenheimer and consensus estimates. Despite this, Oppenheimer maintained its Outperform rating on Savara, emphasizing the company’s clinical progress. Savara also announced a $100 million stock offering of 26,246,720 shares at $3.81 each, managed by firms such as Jefferies, Piper Sandler, and Guggenheim Securities.
Savara recently launched an Expanded Access Program for molgramostim, a potential treatment for patients with autoimmune Pulmonary Alveolar Proteinosis. The company is working towards submitting a Biologics License Application for molgramostim to the FDA in the first half of 2025.
In other company news, Braden Parker was appointed as the new Chief Commercial Officer, bringing over 25 years of experience in the healthcare and biotech industry. Additionally, Savara presented its latest clinical findings at the European Respiratory Society Congress, showcasing research on an inhaled treatment for autoimmune pulmonary alveolar proteinosis.
Moreover, positive results from its Phase 3 IMPALA-2 clinical trial for molgramostim were reported, showing significant improvement in patients. Analyst firms including H.C. Wainwright, JMP Securities, and Piper Sandler have responded positively to these developments, maintaining favorable ratings for Savara and raising their price targets.
InvestingPro Insights
As Savara (NASDAQ:SVRA) continues to progress with its promising aPAP treatment Molbreevi, InvestingPro data provides additional context to the company’s financial position. Despite the optimistic outlook from Oppenheimer, it’s important to note that Savara’s financial metrics reflect its current pre-revenue stage. The company’s market capitalization stands at $699.55 million, with a negative P/E ratio of -9.28 for the last twelve months as of Q2 2024, indicative of its developmental status.
InvestingPro Tips highlight some key aspects of Savara’s financial health. Notably, the company “holds more cash than debt on its balance sheet,” which is crucial for a biotech firm in the development phase. This strong liquidity position is further supported by the fact that “liquid assets exceed short term obligations,” providing Savara with financial flexibility as it moves towards potential commercialization of Molbreevi.
However, investors should be aware that Savara “suffers from weak gross profit margins” and is “not profitable over the last twelve months.” These factors are typical for biotech companies investing heavily in R&D and clinical trials. The recent 8.03% drop in stock price over the last week, as indicated by InvestingPro data, may present an opportunity for investors who share Oppenheimer’s optimistic view on Molbreevi’s potential.
For a more comprehensive analysis, InvestingPro offers 7 additional tips on Savara, providing deeper insights into the company’s financial outlook and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
